GlassScriptPhysician profile
Matthew P Hughes
NPI 1740285527
$4,975.11
in general payments reported to CMS, 2019-2025
27 companies · $1,237 in 2025
The $1,237 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $912 · 2020: $389 · 2021: $342 · 2022: $502 · 2023: $682 · 2024: $911 · 2025: $1,237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,798 · Entertainment: $31.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,798.44 |
| Entertainment | $31.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,516.16 | 2019-2025 | Ngenuity, Lensx, Clareon |
| Sight Sciences, INC. | $503.92 | 2019-2023 | Omni Surgical System |
| Abbvie INC. | $470.97 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $419.55 | 2019-2021 | |
| Allergan, INC. | $259.68 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $243.64 | 2023-2025 | Syfovre |
| Rxsight INC | $216.12 | 2023-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Dompe US, INC. | $186.32 | 2025 | Oxervate |
| Pulmonx Corporation | $160.50 | 2025 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Glaukos Corporation | $113.17 | 2023-2025 | Idosetr |
| Bausch Health US, LLC | $102.44 | 2020 | |
| Novartis Pharmaceuticals Corporation | $93.42 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $90.71 | 2024-2025 | Scoutpro Osmolarity System, Vyzulta |
| Mallinckrodt Hospital Products INC. | $88.41 | 2025 | Acthar |
| Ocular Therapeutix, INC. | $87.26 | 2024 | Dextenza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $71.09 | 2019-2021 | |
| Ivantis, INC | $63.65 | 2019 | |
| Sun Pharmaceutical Industries INC. | $61.56 | 2023-2024 | Cequa |
| Biotissue Holdings INC. | $51.87 | 2022-2025 | |
| Ani Pharmaceuticals, INC. | $31.98 | 2025 | Purified Cortrophin Gel |
| Nova Eye, INC. | $31.09 | 2025 | |
| Thea Pharma INC. | $23.06 | 2024 | Iyuzeh |
| Coherus Oncology, INC. | $21.21 | 2022 | |
| Harrow Eye, LLC | $20.06 | 2024 | Vevye |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Oyster Point Pharma, INC. | $16.89 | 2023 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $10.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Hughes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.